• Explore /
  • Poster
  • / Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.

Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.

Abstract Poster

Authors

Cora Sternberg

Cora N. Sternberg

Weill Cornell Medicine, New York, NY

Cora N. Sternberg , Axel Stuart Merseburger , Ernest Choy , Daniel E. Castellano , Fernando Lopez-Rios , Nicholas James , Giuseppe Luigi Banna , Ugo De Giorgi , Cristina Masini , Aristotelis Bamias , Xavier Garcia del Muro , Thomas Powles , Ignacio Duran , Craig Gedye , Marija Gamulin , Friedemann Zengerling , Lajos Geczi , Sabine de Ducla , Simon Fear , Yohann Loriot

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02928406

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4519)

DOI

10.1200/JCO.2019.37.15_suppl.4519

Abstract #

4519

Poster Bd #

345

Abstract Disclosures

Similar Posters

First Author: Cora N. Sternberg

First Author: Margitta Retz

First Author: Jens Bedke

First Author: Alfonso Gomez De Liano Lista